Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

**Charity Registration No. 1183890 (England and Wales) Charity Registration No. SC049802 (Scotland) Company Registration No. 11911752 (England and Wales)** 

## **LEUKAEMIA CARE** 

**ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024** 


**www.leukaemiacare.org.uk** 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **LEGAL AND ADMINISTRATIVE INFORMATION** 

|**Patrons**|Lady Penny Mountbatten|
|---|---|
||Beverley Warboys|
|**Trustees**|Mr Christopher R. G. Matthews Maxwell|
||(Chair)|
||Mrs W J Davies (Treasurer)|
||Mrs Elizabeth Wilson (Vice Chair)|
||Mr Robert Heppell|
||Mr Dharmesh Mehta|
||Ms Carina Patterson|
||Dr Sarah Searle|
|**President**|Dr Richard Taylor (died 26 June 2024)|
|**Vice Presidents**|Ms Sue Merchant|
||Mr Roland Maturi|
||Professor Claire Harrison|
||Dr Robert Marcus|
||Professor Antonio Pagliuca|
||Ms Sheila Hegarty|
||Mr Jason Eliadis|
||Mr C.R.G. Matthews-Maxwell|
||Mr Peter Mondon|
||Mr Anthony Gavin|
|**Senior Management Team**||
|Chief Executive Officer|Colin Dyer (appointed 2 April 2024)|
|Chief Operating Officer and Deputy CEO|Monica Izmajlowicz|
|Director of Patient Services|Jo Peplow (appointed 1 October 2024)|
|Director of Engagement|Nicole Scully (appointed 30 September 2024)|
|**Medical Advisory Panels**|As descibed in the Trustees' Report|
|**Secretary**|Monica Izmajlowicz|
|**Charity number (England and Wales)**|1183890|
|**Charity number (Scotland)**|SC049802|
|**Company number**|11911752|
|**Website**|www.leukaemiacare.org.uk|
|**Registered office**|One Birch Court|
||Blackpole East|
||Worcester|
||WR3 8SG|





Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **LEGAL AND ADMINISTRATIVE INFORMATION** 

|**Auditor**|Kendall Wadley LLP|
|---|---|
||Granta Lodge|
||71 Graham Road|
||Malvern|
||Worcestershire|
||WR14 2JS|
|**Bankers**|Barclays Bank Plc|
||54 High Street|
||Worcester|
||WR1 2QQ|
|**Solicitors**|Harrison Clark Rickerbys|
||5 Deansway|
||Worcester|
||WR1 2JG|
|**Investment advisors**|Titan Wealth Management Limited|
||2 Greengate|
||Cardale Park|
||Harrogate|
||HG3 1GY|
||CCLA|
||Senator house|
||85 Queen Victoria Street|
||London|
||EC4V  4ET|
||Brewin Dolphin|
||12 Smithfield Street|
||London|
||EC1A 9BD|





Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **CONTENTS** 

||**Page**|
|---|---|
|Trustees' report|1 - 18|
|Statement of Trustees' responsibilities|19|
|Independent auditor's report|20 - 22|
|Statement of financial activities|23 - 24|
|Balance sheet|25|
|Statement of cash flows|26|
|Notes to the financial statements|27 - 45|





Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

The Trustees present their annual report and financial statements for the year ended 31 December 2024. 

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". 

## **Objectives and activities** 

## **About us** 

Leukaemia Care is dedicated to ensuring that everyone affected by leukaemia receives the best possible diagnosis, information, advice, treatment and support. We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). 

## **Purpose** 

The charity’s objects are set out in its Articles of Association: 

1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders. 

2. The relief of need among families, carer's and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders. 

## **Our vision - our long-term ideal** 

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support. 

## **Our mission - What we are doing to make that vision a reality** 

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. 

We provide information, advice and support for anyone affected, this includes patients and their friends and families. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments. 

## **Why our work is important** 

- Leukaemia is the 12th most common form of cancer and 12th biggest cancer killer. 

- Every year, 10,000 people are diagnosed with leukaemia in the UK. 

- Every year, 5,000 people die from leukaemia in the UK. 

- Every year 6,000 people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). 

- Over 50,000 people are living with leukaemia in the UK. 

- There are 34,000 people living with MDS or MPN in the UK. 

- 1 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Our Strategic Goals** 

Our organisational strategy sets five clear goals for our work: 

1. Improving diagnosis – through awareness and early detection. 

2. Ensuring everyone receives high quality information, advice and support. 

3. Tackling issues that impact people’s lives. 

4. Advancing treatment and care. 

5. Creating a narrative to better reflect the reality people experience. 

For more information on our five goals, please visit our website www.leukaemiacare.org.uk 

## **Public benefit** 

Leukaemia Care provides public benefit as a charity through all the charitable information, advice and support service areas detailed above. The Trustees have complied with their duty in accordance with the Charities Act 2011 to have due regard to the Charity Commission’s guidance when reviewing the charity’s aims and objectives, approving funding for projects and services, and in planning and undertaking current and future activities. Taking the Charity Commission’s guidance into consideration, the Trustees are satisfied that our public benefit requirements have been met. 

As examples, our work delivers public benefit by providing information, advice and direct support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment. 

Our HashtagSpot Leukaemia campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment. 

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. 

## **Achievements and performance** 

## **Executive summary** 

Demand for Leukaemia Care’s information and support services grew across most areas in 2024 – as shown by the Charitable Programmes Summary below – while the generosity of our supporters allowed us to exceed expectations in raising funds and, therefore, work to meet that demand and plan further ahead. 

In January 2024, the charity underwent restructuring across all teams and paused or consolidated some activities pending a more in-depth review. 

This allowed us to focus on our core offerings which we identified as our nurse-led advice service (Helpline, WhatsApp and email), welfare and financial support (including grants), counselling, peer-to-peer support through our support groups, Facebook groups and buddy service, advocacy on behalf of individuals, PIF Tick accredited patient information, our hospital Navigator programme, and our SpotLeukaemia campaign. 

We recognised that we were not able to deliver high-quality work in such a broad way, so we either paused or consolidated progammes which included videos, webinars, podcasts, some healthcare professional education and nurse bursaries.  All in-person support groups, bar those linked to a hospital hub, ceased or continued to be run by other parties with us focusing on disease specific online support groups. 

Colin Dyer joined as our new CEO in April, and the charity now has an adapted organisational structure focused on delivery in our key areas of work, the resilience of the organisation, and building the resource to allow Leukaemia Care to secure the funds needed to rise to the challenge of the increases we are seeing in demand for our core services. 

- 2 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Charitable Programmes Summary** 

A breakdown of achievements against our five organisational goals is available in our Strategic Update section below. All funds assigned to Leukaemia Care’s charitable services during the year were consistent with those goals set out in our The Future We Will Create Together strategy (published in 2022 and available at www.leukaemiacare.org.uk). Examples of the allocation of those funds and the continuing increase in demand for our patient services include: 

- Demand for our Welfare Service grew by 20 per cent in 2024, with 1,068 people supported. This includes our own financial grants along with expert assistance for applications for PiP, Attendance Allowance, Employment and Support Allowance, and other key information. 118 people were also supported by our Advocacy Service with issues such as employment rights, insurance, and second opinions. 

- The charity’s Helpline answered 1,315 calls with more than 100,000 minutes spent giving personalised support and guidance. More than 700 WhatsApp messages were also responded to. 

- Leukaemia Care continued to develop its PIF (Patient Information Forum) accredited information in 2024, publishing 36 new or revised information resources, receiving more than 10,000 orders of our printed information booklets, and more than 24,000 webpage views of our online information resources. 

- Eight new Leukaemia Care Hospital Hubs were launched during the year, each hosting one of the charity’s Navigators. Our Navigator team supported 675 people (583 in 2023) with 1,039 in-person appointments and 483 calls. 

- Peer-to-peer support remained a crucial element of our work. Across 26 Support Groups, we held 104 meetings supporting 810 people. Alongside that, 92 new patients or carers were paired with a buddy for support, with 11 new buddies trained. 

- 2.76 million people engaged with our SpotLeukaemia campaign through social media, our campaign videos were watched almost 500,000 times, and the project received 4.79 million views through our digital advertising. 

## **Financial summary** 

- The total income raised during the year was £2,821,699 (£2,112,349 in 2023) with a total expenditure of £2,161,369 (£2,710,249 in 2023). 

- 60.2 per cent of the charity’s expenditure was allocated to our charitable services and projects in 2024. 

- £911,946 of the charity’s income during the year came from legacy donations – including one large legacy of £676,100. 

- The cost of raising funds during the year was £231,937 lower than in the previous year. 

- The charity’s total assets at the end of 2024 stood at £3,212,118. This includes £223,549 of restricted funds, £1,274,302 of designated funds, and £1,714,267 of general unrestricted funds (reserves). This is consistent with the charity’s Reserves Policy as shown on page 12. 

## **Strategic update for 2024 including our plans for 2025** 

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support. 

Our organisational strategy focuses on five clear goals for our work. This report sets out Leukaemia Care’s achievements in each of these priority areas during 2024, along with the charity's goals for the year ahead. 

- 3 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Goal 1: Improving diagnosis – through awareness and early detection** 

We achieve this through our SpotLeukaemia campaign work, targeting awareness days such as World Leukemia Day, our work to influence policy affecting those diagnosed with leukaemia at national and local level, and through our education work with GPs and other healthcare professionals. 

In 2024 we continued our collaboration with Leukaemia UK on the SpotLeukaemia campaign, focusing on raising awareness of the symptoms of leukaemia and the causes of delayed diagnosis. 2.76 million people engaged with our campaign online through social media, we received 4.79 million views via our digital advertising, and our campaign videos were watched almost 500,000 times. 47 pieces of press coverage helped to spread the message, and we generated 82% campaign recall. 

In 2025 we will look to expand the SpotLeukaemia campaign beyond it’s traditional home in September’s Blood Cancer Awareness Month, focus on how we can change individual’s behaviour when they suspect they might have symptoms, and encourage them to see their GP. We will also look at innovative ways to advertise the campaign’s message beyond press and social media. 

Through our policy work, we continue to explore the role of community pharmacists in earlier diagnosis efforts. In Scotland, we met with the team behind the North Cancer Alliance’s lung cancer pharmacist referral pilot scheme to learn more about the trial and what resources would be needed from us to run a similar one in leukaemia. We were informed that there are plans for a second referral pilot scheme and have been asked if we would like to collaborate with the team through offering funding, general support, and other resources. We have also secured a meeting with the Scottish Health Minister alongside Leukaemia UK and aim to raise our concerns over GP recruitment and phlebotomy service capability – and the Royal College of GPs confirmed that they are willing to support our policy call for increased investment in those areas. 

In 2025 we intend to increase the number of organisations with influence into the NHS that support our early diagnosis policy goals, and work to have better input into national and local health plans. 

More than 400 GPs took our acute and chronic leukaemia training in 2024 in association with NHS-funded resource Gateway C and the Royal College of GPs – with more than 90 per cent of those taking the training agreeing that their clinical decision-making changed after completing the courses. We also partnered with the National Association of Sessional GPs to deliver a webinar for GP locums which was a new audience for the charity. In 2025, we will look to assess our role in GP training and awareness and ensure we have input into the best platforms and communication to achieve this. 

## **Goal 2: Ensuring everyone receives high quality information, advice and support** 

High quality information, advice and support is key for people diagnosed and living with leukaemia, and those around them. This area of work covers our core direct services for patients and their carers and families including our written information (hard copy and online), advice service (incorporating the Helpline, WhatsApp, and email), advocacy casework and welfare advice, Navigators in our Hospital Hubs, support groups and forums, one-to-one buddy support, financial grants, and counselling. 

Leukaemia Care continues to provide PIF (Patient Information Forum) Tick accredited information for patients and their families and, to maintain quality and meet demand, we recruited two new Patient Information Writers during the year. We published 36 new or revised information resources in 2024 – and had more than 10,000 orders of our printed information booklets and more than 24,000 webpage views of our online leukaemia information resources. In total, 93% of people responding to our pop-up survey rated our information as helpful. In 2025, we will continue to develop materials to both update existing information and develop new resources where demand exists, while also working to improve our delivery of information using the advancing technology now available and for those harder to reach patients where, for example, language may be a barrier. 

Alongside our information, we offer the opportunity to seek advice and support directly from our Clinical Nurse Specialists, trained advocates, and welfare advisors. 

In 2024, we added a second Nurse to our Helpline team, and answered 1,315 calls to that service with more than 100,000 minutes spent giving personalised support, information and an essential listening ear. 700 WhatsApp messages were responded to. This essential service will continue to be developed in 2025, with demand forecast to increase as some of the charity’s other outreach areas grow. 

- 4 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

Demand for our Welfare Service grew by 20 per cent in 2024 with 1,068 people supported with financial grants along with applications for blue badges, PIP, Attendance Allowance, Employment and Support Allowance, housing support and information. We provided more than £105,000 in small financial grants from our cost-ofliving fund and, in 2025, we will also look to add a small number of exceptional hardship grants for those people who are unable to access any support from elsewhere. 

_“I got an email from Lisa from Leukaemia Care who was very professional and friendly. At the time I felt like I couldn’t talk to anyone in my life as no one was helping, and I was just locking all of my friends and family out. Lisa was the only one person that helped me and got me back on the right path. She helped me fill out forms and get disability benefits that I had applied for previously and got turned away. She was the only one that said "your lifestyle isn’t what it should be and we will get you back on your feet"._ 

Also, 118 (204 in 2023) people have been supported by the Advocacy Officer, with the most popular topics being employment rights, accessing travel insurance and second opinions. Employment queries made up more than one-fifth of all enquiries with an increase in patients seeking support due to issues with their employers, mainly coming from chronic patients who want to understand their rights at work and explore what they are entitled to, including reasonable adjustments and discrimination. In 2025 we will enable the Welfare and Advocacy teams to have more focus by adding further resource to the team focused on counselling (see below) and investigating the better use of technology to improve the speed of casework. 

Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or non-existent. In 2024, we supported 84 people (63 in 2023) with more than 500 counselling sessions to support with issues such as bereavement, coping with a diagnosis either as a patient, parent or child, coping with chronic leukaemia, and managing anxiety following a relapse. 

The growth of the Leukaemia Care Navigator team working directly with patients in our Hospital Hubs around the UK was a priority in 2024, and will continue to be so in 2025. During the year, we secured agreements for 12 new hospital hubs, eight of which became operational during the year. The remaining four will become operational in 2025. 

Our 21 hospital hubs can be found in Derriford Hospital Plymouth, Royal Gwent Hospital, Freeman Hospital Newcastle, Bournemouth Hospital, Southampton General – acute clinic and CLL clinic, Royal Sussex Hospital (Brighton), Nottingham Hospital, Great Western Hospital (Swindon), Belfast Hospital, Antrim Hospital, Beatson Hospital (Glasgow), Queen Elizabeth Hospital (Glasgow), Victoria Hospital (Glasgow), Solihull Hospital (West Midlands), Heartlands Hospital (Birmingham), St James Hospital (Leeds), University of Bristol Hospital, The Christie (Manchester), University College London Hospital, and Norfolk and Norwich Hospital. 

Our Navigators provide emotional support, information and advice to patients and their families within haematology departments and on hospital wards, at diagnosis and throughout their treatment. In 2024, we supported 675 people (583 in 2023), with 1,039 in person appointments and 483 calls. The navigators also made 850 referrals to the charity’s services. 

In 2025 we will also carry out a detailed piece of research into the impact of, and demand for, the Navigator 

service to help inform next steps with this programme. 

Peer-to-peer support remains a crucial element of the charity’s portfolio of support. Across 26 groups covering different leukaemias and myeloproliferative neoplasms, we held 104 support group meetings during the year, supporting 810 people. Alongside that, 92 new patients or carers have been paired with a buddy for support, with 11 new buddies trained. Development plans for both programmes will be created in 2025. 

_“I can't tell you how comforting (and a relief) to talk to someone who understands exactly what having this illness means! My buddy was so lovely and very chatty which made our chat so easy. What a brilliant idea, so thankyou so much.”_ 

In addition, our CAR-T Away From Home service – supported through our much-valued partnership with the Dalata Hotels Group – provided vital help for 20 families through grants and hotel stays. This service provides patients undergoing CAR-T treatment and their families access to paid hotel rooms and a £500 grant towards increased costs. 

- 5 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

Most of the families who apply for the service have been told about it by their CAR-T clinical nurse specialist (CNS), highlighting the importance of sharing what we do with healthcare teams so that they can continue to refer new patients into the service. In 2025, we plan to work with more clinical teams to increase the awareness of this service and, therefore, generate more referrals – especially as we are the only charity offering this specific type of support (hotels and grants) to leukaemia patients undergoing CAR-T therapy. 

## **Goal 3: Tackling issues that impact people’s lives** 

Ensuring that Leukaemia Care is able to understand the issues facing people with leukaemia and those caring for them (both personally and professionally) is essential to our work, allowing us to push where appropriate for improvements in care and support. 

In 2024, we were successful in making a switch from MPs and Government as our main targets to influence stakeholders who deal with patient issues day-to-day at a more local level. In 2025 we will continue this and work to deepen our relationship with Cancer Alliances and local NHS bodies. 

The charity continues to examine the best way for the holistic care experience of leukaemia care patients to be improved, and for there to be an accepted ‘standard of care’ for those patients across the UK. Work in 2024 has led to the creation of a working group within our Nurse Advisory Group to take on this project, and meetings are planned with the UK Oncology Nursing Society (we were present at their conference in 2024) and the UK Acute Oncology Society among others in 2025 with the aim of publishing a draft Standards of Care document. 

In addition, we have collaborated with other charities in 2024 to raise the issue of the financial impact of a leukaemia diagnosis, and will continue to develop this work in 2025 including the problem of Sick Pay for patients. 

In Scotland, we are continuing to work with other charity colleagues through the Scottish Cancer Coalition Early Diagnosis Group and the Blood Cancer Alliance on the issue of data availability in the country, and have met with the Scottish Government’s Centre for Sustainable Delivery to discuss issues around new measures of early diagnosis for blood cancers. 

The importance of completing high-quality research to support our work and inform our strategy was also underlined in 2024, and a detailed piece of work on the impact of, and demand for, our Navigator programme will be completed early in 2025. This project has included input from students at the University of Oxford, and will be continued across other Leukaemia Care programmes in the coming year. 

## **Goal 4: Advancing treatment and care** 

The charity has continued to bring health professionals together to help inform best practice for Leukaemia Care patients, and to engage those professionals in our work to ensure we are providing care and support in the best possible way. 

127 medical professionals volunteered their time during the year (116 in 2023) – joining Support Group meetings, and working with our Information Team on new or updated resources, for example. Also, our Nurse Forums continued during the year with 82 health professionals attending (126 in 2023). In 2025 we will consult with those professionals close to us to ensure that we are engaging with them in the most productive way, and to identify other areas of our work where additional input from volunteer health professionals would benefit our services. 

The charity’s work to ensure the best access to treatment for patients also includes our involvement in relevant Heath Technology Appraisals for leukaemia, MDS and MPN to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. We supported 10 of these in 2024. 

This includes collaborative projects – for example our work with Leukaemia UK and Anthony Nolan on a new type of CAR-T treatment being appraised by NICE (National Institute for Health and Care Excellence). 

We will continue to assess our role in both appraisals and in contributing to medical policy changes in 2025. 

- 6 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Goal 5: Creating a narrative to better reflect the reality people face** 

Communicating with people through our own communication, traditional or social media is essential in reaching those people that need us, those that fund us, and in increasing the wider understanding of the reality of living with leukaemia. 

An average increase of 11 per cent in the reach of our own magazine and newsletter was achieved in 2024, with around 10 per cent more people opening our monthly online newsletter when compared to the previous year. 

We increased our reach across all social media platforms, and saw our videos viewed more than 667,000 times (578,000 in 2023). This was helped by a successful SpotLeukaemia campaign backed by celebrity TV Doctor Amir Khan whose posts received more than 200,000 views. 

We also secured more than 100 pieces of press coverage and were able to place the issues of a leukaemia diagnosis into millions of homes around the country thanks to a partnership with the ITV tv show Emmerdale which saw our Helpline lead Nurse work with the ITV scriptwriters on a leukaemia-related storyline which ran for many weeks in the Spring and Summer. 

Our website saw a reduction in the number of sessions in 2024 – but the time spent by each person on our site increased by more than 20 per cent as we worked to improve the quality of our information and navigation. 

In 2025, two pieces of work will begin with a view to increasing our reach – a consultation on the effectiveness of the Leukaemia Care brand and messaging, and a project to examine the better use of technology including our website’s accessibility, its use for delivery of information across different platforms and devices, and planning for technological advances including AI. 

## **Fundraising summary** 

## **Our approach to fundraising** 

Leukaemia Care is registered with the Fundraising Regulator and, therefore, agrees that when fundraising we will do so in accordance with the Fundraising Promise and the Code of Fundraising Practice as it applies to our fundraising methods. We agree to promote the Fundraising Promise (https://www.fundraisingregulator.org.uk/) and to include the Registration Badge on our fundraising materials where practical. 

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person’s privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask. 

In 2024, the charity received no suppression requests through the Fundraising Preference Service and no fundraising complaints. 

Our complaints procedure can be found on our website https://www.leukaemiacare.org.uk/about-us/ 

2024 was a year of over-achievement in terms of funds raised by the charity. A total income of £2,821,699 was secured – almost £750,000 ahead of the year’s target budget and more than £700,000 higher than in the previous year. 

Much of that increase was due to the generosity of some supporters in leaving legacy donations to the charity – totaling £911,946. 

With 257 runners taking part in the London Marathon for Leukaemia Care, we were able to raise £776,000 from that event, and other challenge event participants added a further £250,000 (approx.) to our funds. 

Once again we were incredibly grateful to the staff and customers at the Dalata Hotels Group. Their support saw that partnership raise more than £70,000 for our work, and in 2025 we aim to build an even closer relationship with the company through the addition of a dedicated account manager. 

Fundraising support came in all shapes and sizes for the charity during the year, and donations from individuals, community groups, and those remembering close ones affected by leukaemia raised more than £300,000 – exceeding expectations as we worked to improve our messaging and outreach. 

- 7 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

That was helped by the airing of our BBC Lifeline appeal, hosted by Arlene Phillips early in 2024, giving the charity two, nine-minute slots on BBC Television and featuring a number of patient stories and the positive impact Leukaemia Care has had on their lives. 

With no major event taking place in 2024, and a re-structure of the fundraising team, costs in this area were reduced by around 20 per cent during the year. 

## **Pharmaceutical grants** 

Leukaemia Care collaborates with the pharmaceutical industry to ensure that the interests of patients are considered during the development of new drugs and treatments. Our patient advisory work plays an important role in making sure treatments are thoroughly appraised and person-centred before they are made available to the public. As a way of helping us remain secure and to continue to be effective in our work with patients, many pharmaceutical companies provide us with funding throughout the year. This funding is always received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care's own Code of Practice (see our website). 

To ensure that we remain financially independent, limits are placed on all types of grant income. We do not allow the level of funding received from the pharmaceutical industry to exceed 25% of our total annual income, nor do we allow the funding received from any individual company to exceed 10% of our total annual income. 

In 2024 we were grateful for the following support from pharmaceutical companies which totaled £167,764. Please note, this is funding that was received in 2024 – any funding that was intended for 2024 but not received until 2025 will be acknowledged in the annual report and accounts for 2025. 

- Abbvie - £20,000 towards patient information 

- Amgen - £6,000 towards AML videos 

- Amgen - £1,000 

- Astellas - £5,000 towards Spot Leukaemia work 

- AstraZeneca UK - £15,000 towards hospital hubs 

- Beigene - £45,764 towards side effects helpline 

- Bristol Myers Squibb – £10,000 towards core funding 

- Gilead - £20,000 

- Janssen - £5,000 towards core services such as helpline 

- Elly Lily - £10,000 towards Blood Cancer Awareness Month 

- Takeda Pharmaceuticals - £30,000 towards core funding 

## **Grants and trusts** 

Leukaemia Care receives no statutory funding, but it does receive grants from independent trusts and other funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We would like to thank the following funders who kindly pledged their support in 2024. Please note, this is grant funding that was received in 2024 – any funding that was pledged for 2024 but not received until 2025 will be acknowledged in the annual report and accounts for 2025. 

- Alice Ellen Cooper-Dean Charitable Foundation 

- Barbour Foundation 

- Chalk Cliff Trust 

- Charles and Elsie Sykes Trust 

- Childwick Trust 

- Ceramex Ltd 

- Edgar E Lawley Foundation 

- Esme Mitchell Trust 

- E H Smith Charitable Trust 

- Florence Trust 

- Frazer Trust 

- Fullagar Charitable Trust 

- G J W Turner Trust 

- Hodge Foundation 

- 8 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

- Ian Askew Charitable Trust 

- Jesse Spencer Trust 

- John James Bristol Foundation 

- Johnson Charitable Trust 

- James T Howatt Charitable Trust 

- Kilpatrick Fraser Charitable Trust 

- Leukaemia and Lymphoma Northern Ireland 

- Leukaemia UK 

- Manson Family Charitable Trust 

- Mills and Reeve Charitable Trust 

- Medicash Foundation 

- Marsh Charitable Trust 

- National Lottery (2 separate grants) 

- Paul Bassham Charitable Trust 

- Pennycress Trust 

- Rothley Trust 

- Simon Gibson Charitable Trust 

- Strangward Trust 

- Sovereign Health Care Charitable Trust 

- Santa Barbara Heights Charitable Trust 

- Sir Robert Gooch Charitable Trust 

- Sir John Eastwood Foundation 

- Templeton Goodwill Trust 

- Thistledown Trust 

- The Access Foundation 

- The 29 May 1961 

- The Cumber Family Charitable Trust 

- The George Family Foundation 

- The Eveson Charitable Trust 

- The Lawson Trust CIO 

- The Burford Trust 

- The Patrick Trust 

- The Geoffrey Watling Charity 

- William Allen Young Charitable Trust 

- W E Dunn Trust 

## **Grant making by Leukaemia Care** 

Leukaemia Care has three grant making streams: the Cost of Living with Leukaemia Fund, the Leukaemia Counselling Fund, and the CAR-T Away from Home Service. These contribute to addressing the recommendations made in our Living with Leukaemia reports which inform our strategic aims. 

## � **Cost of Living with Leukaemia Fund** 

This fund provides grants of up to £175 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month. 

- 9 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## � **The Leukaemia Counselling Fund** 

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £420. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year. 

## � **CAR-T Away from Home Service** 

CAR-T (Chimeric Antigen Receptor) cell therapy is a type of treatment for leukaemia that has revolutionised the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia (ALL) but is expected to change the way other forms of leukaemia patients are treated in the future. The way the therapy is delivered means that patients often have long periods of waiting and spending time near to hospital to receive the treatment. 

People can apply for accommodation, grant funding or both with one grant per family. This grant is only open to those currently going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund does not have a closing date and funds are allocated on a first- come first-served basis until the fund is depleted. 

Thanks to our hotel partner Dalata, we can offer free accommodation in one double or twin room per family per stay for up to 30 days. This is booked and arranged by Leukaemia Care, and we must know the dates in advance. This cannot be exchanged for money, vouchers, or another hotel. 

We will also pay up to £500 in a cash grant to help with other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc. 

## **Volunteers** 

Our volunteers play a crucial role in ensuring that we provide essential support to individuals affected by leukaemia, MDS, or an MPN. Some volunteers offer direct support to patients and carers, while others contribute by advising on our information resources or assisting with fundraising efforts. Each volunteer brings unique experience and value, whether they are a patient, clinician, carer, or supporter. 

In 2024, we developed and refined our volunteering programs, enhancing training, support, and engagement opportunities to create a more effective and rewarding experience for our volunteers. 

## � **Buddies Scheme** 

The Buddy Scheme remains one of our most significant volunteer-led programs, providing one-on-one support to patients and carers from trained volunteers who have first-hand experience with a leukaemia, MPN, or MDS diagnosis. In 2024, we implemented several key changes: 

- The scheme was overhauled, transitioning to a 12-week support model with an optional 12-week extension. This change has increased capacity and improved the safety and effectiveness of the program for both volunteers and beneficiaries. 

- A new, custom-made buddy volunteer training program was introduced via our eLearning system (provided by the Charity Learning Consortium). This comprehensive training covers active listening, safeguarding, signposting, mental health awareness, and suicide awareness. 

- A recruitment drive toward the end of 2024 resulted in 11 new buddies completing training, with several more set to finish in early 2025. Our goal for 2025 is to train an additional 40 buddies to meet growing demand. 

- The management of the scheme was transitioned from spreadsheets to project management software Asana. By doing this we have improved efficiency and coordination. Asana allows for better task assignment, real-time progress tracking, and streamlined communication, making it easier to manage volunteers, track patient interactions, and ensure smooth program operations. 

- In 2024, volunteers provided support to 90 new patients and carers—almost three times the number assisted in the previous year. 

- 10 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## � **Advisory Panel** 

In 2024, our Patient Advisory Panel was restructured to become a more inclusive "Advisory Panel," welcoming not only patients but also family members, carers, and those who have lost loved ones to leukaemia. Additional improvements included: 

- Implementing a focus group system, where groups of up to 12 volunteers met throughout the year to provide feedback on topics such as patient information, volunteering roles, campaigns, legacies, wills, and our website. 

- Creating an Asana project to manage and coordinate the panel’s activities efficiently. 

- While membership remained stable, a few new members joined as some original members left. Active recruitment will resume in 2025 as the panel settles into its revised format. 

- **Patient Information Reviewers** 

Patient and carer volunteers played a key role in updating and improving our information resources in 2024. Notable contributions included: 

- 34 volunteers participated, with at least 10 being new to volunteering with our charity. 

- A total of 32 individual patient information resources were revised or newly published with the assistance of volunteer reviewers. These included booklets, website information, an animation, factsheets and leaflets. 

- 

- **Facebook Support Group Moderators** 

Our Facebook support groups continued to be a valuable resource for patients and carers. However, the number of volunteers moderating these groups declined to five in 2024. Despite this, the remaining volunteers provided crucial support by answering questions and signposting individuals to Leukaemia Care services when needed. Looking ahead to 2025: 

- The Patient Engagement Officer will begin overseeing the groups to enhance engagement. 

- A recruitment and training initiative will be launched to attract new moderators and raise the profile of these groups. 

- **Medical Advisory Panel** 

The Medical Advisory Panel continued to play a vital role in 2024, ensuring that healthcare professionals remain actively involved in our work. Key activities included: 

- Five panel meetings took place, with two sessions dedicated to nurses, two to haematology specialists, and one to GPs. 

- Healthcare professionals also contributed as speakers and facilitators for our support groups. 

## **Looking Ahead to 2025** 

As we move into 2025, our focus will be on expanding volunteer engagement, improving training and support systems, and ensuring that our programs continue to meet the needs of patients and carers. Key priorities include: 

- Training 40 new buddies to enhance the capacity of the Buddy Scheme. 

- Expanding the Advisory Panel’s membership and optimizing its focus group system. 

- Recruiting and training additional Facebook support group moderators. 

- Continuing to integrate volunteers into the development of patient information resources. 

- Reviewing and restructuring our Medical Advisory Panels using a similar approach to the one taken for our patient and carer panel. 

We are incredibly grateful to all our volunteers for their dedication and commitment, and we look forward to building on these successes in the coming year. 

- 11 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Risk assessment and management** 

The Board of Trustees approved an updated Risk Register during the year as part of its on-going work to ensure compliance with the Charity Governance Code. That Risk Register is a standing item on Board meeting agendas, and is fully reviewed at each AGM alongside the Senior Management Team to ensure any risks the charity may face in the forthcoming year are addressed. 

## Key areas include: 

- Ensuring the charity remains aligned to the blood cancer environment 

- Quality training for all staff – especially those with patient-focused roles 

- Sustainability of funds – and the allocation of restricted funds 

- Financial controls 

- Information security and data protection 

- IT security 

- Compliance with fundraising regulations 

In addition, a full update, financial, and progress report including any identified or potential risks is provided to the Board by the CEO and COO quarterly, allowing Trustees to monitor progress against the charity’s strategic objectives. 

The Board of Trustees approves a detailed annual budget at its Autumn meeting (including cashflow and scenario planning), and the regular financial report provided to the Board identifies all changes in forecasts when compared to that budget. 

In 2025, the Board is committed to the development of its Governance Sub-Committee with responsibility for analysis of the Risk Register. In addition, the charity has a schedule of regularly assessed and updated key policies and procedures (including Business Continuity Plan) covering all areas identified by the Risk Register. 

The Trustees are confident that reasonable systems have been established to identify, mitigate, and manage new and existing risks, and that forward planning will enable the charity to be prepared for all future eventualities. 

Trustee Indemnity insurance of £5,000,000 is in place. 

## **Our Reserves Policy** 

Leukaemia Care’s reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively. 

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold 

reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily. 

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term. 

It is Leukaemia Care’s policy to express reserves in terms of ‘months of expenditure’ for the purposes of external communications. 

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once): 

- Liabilities and contingencies - i.e. staffing costs to provide services, wind-down costs based on the costs of closing down the Charity. 

- Provision to absorb setback - i.e. predominantly related to income-based risk. 

- Funds designated for specific commitments – i.e. operational plan commitments, including forecast deficits or existing committed projects and activities. 

- 12 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

In line with the considerations above, Leukaemia Care’s policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure. Ongoing expenditure excludes one-off projects and depreciation, which are met through designation. 

Our policy is subject to annual review by the Board of Trustees at each AGM, with the reserves also reviewed in line with the policy at the Autumn Board meeting where the following year’s budget is approved. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter. 

## **Our Investment Policy** 

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The Investment Policy is reviewed annually, and recommendations made to Trustees. Day-to-day investment management is delegated to authorised, professional investment advisors, regulated by the FCA. 

Our Investment Policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term, but also to be ‐ available at short notice to support the on going activities of Leukaemia Care. 

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements. 

## **Structure, governance and management** 

## **Constitution** 

This is the fourth annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802). 

## **Trustees and their role** 

The Trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 Trustees in office at any one time are required by the constitution. At each AGM one-third of the Trustees, must retire from office but may stand for re-election. A Trustee’s term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to Trustee meetings. The Trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team. 

The Trustees who served during the year and up to the date of signature of the financial statements were: 

Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis (resigned 31 July 2024) Ms E Wilson (Vice Chair) Ms Kate Stallard (resigned 26 June 2024) Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland (resigned 6 November 2024) Ms Carina Patterson Helen Knight (resigned 4 November 2024) Dr Sarah Searle 

We are grateful for the support of the clinicians on our Trustee Board some of whom unfortunately due to the pressure of their workload as healthcare professionals resigned in the latter two quarters of 2024. Dr Nikolousis had been a Trustee for many years and supported Leukaemia Care to pilot its first hospital hub at Birmingham Heartlands Hospital in his clinic.  Professor Copland joined as a Trustee in 2022 but supported the charity for years prior to that on our medical advisory panel, and as a conference and webinar speaker.  Helen Knight also served as a Trustee since 2022 and continues to provide her insight and support with our Nottingham CLL support group, our Nurse Forum and Nottingham Hospital Hub. 

- 13 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

A special mention to Kate Stallard who as one of our patient representatives on the Board fronted many of our campaigns including our first Radio 4 appeal as well as our SpotLeukaemia campaign.  After treatment, Kate retrained as a counsellor and now has a busy private practice. 

## **Recruitment, induction and training of Trustees** 

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity’s strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care’s social media outlets, online recruitment sites, specialist publications targeting, for example, healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, are interviewed by a number of the current Board. Successful applicants are co-opted as Trustees until their formal election at the next AGM. 

On appointment, the new Trustees attend an induction at our offices in Worcester with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity’s strategy as well as helpful publications such as the Charity Commissions “The Essential Trustee”.  Trustees are also asked to complete the free online Trustee training provided by ICAEW which outlines their duties and responsibilities.  Any trustee that takes on a specific role such as Safeguarding Trustee are provided with additional training relevant to their specialist role. 

In 2025, the Board will carry out a further Skills Audit and Board Effectiveness Survey to identify key areas for improvement on the Board through recruitment. 

## **Our trading subsidiary** 

Ahead of the launch of our art trail Unicornfest which took place in 2023, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its Directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest went through the subsidiary company.  It has not been used for any other purpose since the trail ended in 2023. 

## **Senior Management Team** 

The Trustees delegate day-to-day operations of the charity to the executive team. Chief Executive Officer (joined 2 April 2024) Colin Dyer Chief Operating Officer and Deputy CEO Monica Izmajlowicz Director of Engagement Nicole Scully Director of Patient Services Jo Peplow 

## **Our Patrons** 

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys. 

## **Our President and Vice-Presidents** 

It is with great sadness that we announce that our President, Dr Richard Taylor died 26 June 2024. Richard was not only a president of Leukaemia Care for 15 years but also a friend to the charity and the people we help. 

He was a staunch advocate for leukaemia patients and a man who embodied the six core NHS values of care, compassion, competence, communication, courage and commitment. We will miss our friend and are grateful he chose to support our community. 

President Dr Richard Taylor (died 26/06/2024) 

- 14 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

Vice Presidents 

Ms. Sue Merchant Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr Roland Maturi Mr Christopher Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin 

## **Medical advisory panels** 

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time. 

Acute lymphocytic leukaemia panel 

Prof. Adele Fielding Dr. Anthony Moorman Prof. Oliver Ottmann Dr. Nick Morley Dr. Sara Ghorashian Prof. Ajay Vora Dr. Tobias Menne Dr. Claire Rowntree Acute myeloid leukaemia panel Prof. Mary Frances McMullin Dr. Steve Knapper Prof. Rachael Hough (SCT adolescent leukaemia) Dr. David Taussig Dr. Priyanka Mehta (AML & CML) Dr. Panagiotis Kottaridis Dr. Mike Dennis Dr. Ann-Louise Latif Prof. Nigel Russell Chronic lymphocytic leukaemia panel Assoc. Prof. Anna Schuh Prof. Chris Fegan Prof. Guy Pratt Assoc. Prof Francesco Forconi Prof. Adrian Bloor Dr. Shankara Paneesha Dr. Alison McCaig Dr. Niamh Appleby Dr. George Follows Prof. Christopher Fox Prof. John Gribben Dr. Nicolas Martinez-Calle Chronic myeloid leukaemia panel Dr. Dragana Milojkovic Prof. Jane Apperley Prof. Stephen O’Brien Prof. Mhairi Copeland Dr Jonathan Kell Dr. Nilima Parry-Jones Dr. Piers Patten Dr. Renata Walewska Dr Sunil Lyengar 

- 15 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Other blood cancers panel** 

Prof. Claire Harrison (MPN) Dr. Claire Dearden (HCL) Dr. Richard Kelly (Aplastic anaemia, MDS) Prof David Bowen (MDS) Dr Dima El-Shakari (LGLL, ALL, CLL) Prof. Rachel Hough Prof. Adam Mead 

## **GP advisory Panel** 

Dr. Rebecca Chellaswamy Dr. Elaine Hampton Dr. Tom Kneale Dr. Anish Kotecha Dr. Lily Lamb Dr. Rachael Marchant Dr. Pawan Randev Dr. Richard Roope Dr. Lance Saker Dr Sarah Smith (Searle) Dr. Neil Smith Dr. Sarah Taylor Prof. David Weller 

## **Nurse advisory panel** 

Sarah Blakey Alicia Harris Joanna Large Catherine Langton Sarah Watmough Jacqueline Stones Joanna Stokes Alison Pugh Phyllis Paterson Lianne Palmer Aileen Nield Klara Matulay Laura Ledger Helen Knight Caroline Kerr Michelle Kenyon Tracy Gunter Catherine Griffiths Kirsty Crozier Marife Colis Andrea Wooltorton Aine Sheerin O'Neil Jackson Alice Ryan Bryony Tyrell Claire Ballantyne Sheri Thompson Tina Brooks Alison York Matthew Fowler Christina Kirby Eleanor Pearce Catherine Chapple 

- 16 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Remuneration policy** 

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively. When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010. 

The Board of Trustees are responsible for setting remuneration levels for the senior management team; CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy. 

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage. 

The remuneration policy is reviewed annually by Trustees, normally at their meeting in November. Salaries are reviewed annually in March following annual appraisals and take effect from April. A salary review does not imply an increase and in making any pay award the review will be based on the organisation’s financial health. 

When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors: 

- Mission and strategic aims of the charity and its general day-to-day needs. 

- Consistency of equivalent roles across the charity and how any decision might impact on the overall remuneration policy. 

- Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties. 

- Current strategic business plan and how this might affect current and/or future needs. 

- Leukaemia Care’s financial ability to pay. 

- Available information on charitable sector pay levels, alongside that of other sectors. 

- Available information on regional pay levels 

- The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development. 

- The charity’s track record in recruiting and retaining high-performing staff. 

- The potential impact of any decision on the charity’s reputation with beneficiaries, donors and the wider public. 

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO. 

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale. 

The Board of Trustees is committed to including the following information within its annual statutory report and financial statements: 

- A summary statement of the charity’s remuneration policy and approach to senior management pay. 

- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer’s national insurance) paid to the Senior Management Team, in line with the accounting Statement of Recommended Practice 2019 for charities. Given the charity’s size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public. 

## **Pensions** 

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST. 

- 17 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **Related parties** 

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail. 

## **Auditor** 

In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting. 

## **Disclosure of information to auditor** 

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information. 

The report has been prepared having take advantage of the small companies regime in the Companies Act 2006. 

The Trustees' report was approved by the Board of Trustees. 


## **Mr Christopher R. G. Matthews Maxwell (Chair)** 

Trustee Dated: 25 June 2025 

- 18 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

The Trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year. 

In preparing these financial statements, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charities SORP; 

- make judgements and estimates that are reasonable and prudent;  and 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation. 

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

- 19 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE** 

## **Opinion** 

We have audited the financial statements of Leukaemia Care (the ‘Charity’) for the year ended 31 December 2024 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 _The Financial Reporting Standard applicable in the UK and Republic of Ireland_ (United Kingdom Generally Accepted Accounting Practice). 

In our opinion, the financial statements: 

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended). 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the _Auditor's responsibilities for the audit of the financial statements_ section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## **Opinons on other matters prescribed by the Companies Act 2006** 

In our opinion, based on the work undertaken in the course of our audit: 

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report prepared for the purposes of company law, is consistent with the financial statements; and 

- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements. 

- 20 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE** 

## **Matters on which we are required to report by exception** 

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion: 

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or 

- sufficient and proper accounting records have not been kept; or 

- the financial statements are not in agreement with the accounting records; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of Trustees** 

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the Charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. 

## **Auditor's responsibilities for the audit of the financial statements** 

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below. 

## **Extent to which the audit was considered capable of detecting irregularities and fraud** 

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities including fraud and non-compliance with laws and regulations was as follows: 

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained. 

- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made. 

- an review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities. 

- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the company. 

- 21 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE** 

## **Audit response to risks identified** 

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material misstatements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error. 

- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed. 

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any. 

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report. 

## **Use of our report** 

This report is made solely to the charity’s trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed. 


## **Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor) for and on behalf of Kendall Wadley LLP** 

25 June 2025 

**Chartered Accountants Statutory Auditor** 

Granta Lodge 71 Graham Road Malvern Worcestershire WR14 2JS 

Kendall Wadley LLP is eligible for appointment as auditor of the Charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006. 

- 22 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

|**Current financial year**<br>**Unrestricted**<br>**Restricted**<br>**funds**<br>**funds**<br>**2024**<br>**2024**<br>**Notes**<br>**£**<br>**£**<br>**Income and endowments from:**<br>Donations and legacies<br>**3**<br>1,286,476<br>299,383<br>Fundraising income<br>**4**<br>1,195,916<br>-<br>Investments<br>**5**<br>38,431<br>-<br>Other income<br>**6**<br>1,493<br>-<br>**Total income**<br>2,522,316<br>299,383<br>**Expenditure on:**<br>Raising funds<br>**7**<br>861,052<br>-<br>Charitable activities<br>**8**<br>1,076,141<br>224,176<br>Material other expenditure<br>**13**<br>-<br>-<br>**Total expenditure**<br>1,937,193<br>224,176<br>Net gains on investments<br>**14**<br>46,609<br>-<br>**Net income/(expenditure)**<br>631,732<br>75,207<br>**Other recognised gains and losses**<br>Revaluation of tangible fixed assets<br>**16**<br>(67,598)<br>-<br>**Net movement in funds**<br>564,134<br>75,207<br>Fund balances at 1 January 2024<br>2,424,435<br>148,342<br>**Fund balances at 31 December 2024**<br>2,988,569<br>223,549|**Total**<br>**2024**<br>**£**<br>1,585,859<br>1,195,916<br>38,431<br>1,493<br>2,821,699<br>861,052<br>1,300,317<br>-<br>2,161,369<br>46,609<br>706,939<br>(67,598)<br>639,341<br>2,572,777<br>3,212,118|Total<br>2023<br>**£**<br>840,277<br>1,237,052<br>34,057<br>963<br>2,112,349<br>1,092,989<br>1,415,130<br>202,130<br>2,710,249<br>30,632<br>(567,268)<br>12,640<br>(554,628)<br>3,127,405<br>2,572,777|
|---|---|---|



The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. 

- 23 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED) INCLUDING INCOME AND EXPENDITURE ACCOUNT** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

|**Prior financial year**<br>**Unrestricted**<br>**Restricted**<br>**funds**<br>**funds**<br>**2023**<br>**2023**<br>**Notes**<br>**£**<br>**£**<br>**Income and endowments from:**<br>Donations and legacies<br>**3**<br>591,126<br>249,151<br>Fundraising income<br>**4**<br>1,237,052<br>-<br>Investments<br>**5**<br>34,057<br>-<br>Other income<br>**6**<br>963<br>-<br>**Total income**<br>1,863,198<br>249,151<br>**Expenditure on:**<br>Raising funds<br>**7**<br>1,092,989<br>-<br>Charitable activities<br>**8**<br>1,158,403<br>256,727<br>Material other expenditure<br>**13**<br>202,130<br>-<br>**Total expenditure**<br>2,453,522<br>256,727<br>Net gains on investments<br>**14**<br>30,632<br>-<br>**Net income/(expenditure)**<br>(559,692)<br>(7,576)<br>**Other recognised gains and losses**<br>Revaluation of tangible fixed assets<br>**16**<br>12,640<br>-<br>**Net movement in funds**<br>(547,052)<br>(7,576)<br>Fund balances on incorporation at 1 January 2023<br>2,971,487<br>155,918<br>**Fund balances at 31 December 2023**<br>2,424,435<br>148,342|**Total**<br>**2023**<br>**£**<br>840,277<br>1,237,052<br>34,057<br>963<br>2,112,349<br>1,092,989<br>1,415,130<br>202,130<br>2,710,249<br>30,632<br>(567,268)<br>12,640<br>(554,628)<br>3,127,405<br>2,572,777|
|---|---|



The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. 

- 24 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **BALANCE SHEET** 

## _**AS AT 31 DECEMBER 2024**_ 

|**Notes**<br>**Fixed assets**<br>Tangible assets<br>**16**<br>Investments<br>**17**<br>**Current assets**<br>Stocks<br>**19**<br>Debtors<br>**20**<br>Investments<br>**21**<br>Cash at bank and in hand<br>**Creditors: amounts falling due within**<br>**one year**<br>**22**<br>Net current assets<br>**Total net assets**<br>**Income funds**<br>Restricted funds<br>**24**<br>Unrestricted funds<br>Designated funds<br>**25**<br>General unrestricted funds|**2024**<br>**£**<br>**£**<br>806,869<br>698,764<br>1,505,633<br>-<br>332,322<br>313,222<br>1,180,908<br>1,826,452<br>(119,967)<br>1,706,485<br>3,212,118<br>223,549<br>1,274,302<br>1,714,267<br>2,988,569<br>3,212,118|**2023**<br>**£**<br>**£**<br>887,448<br>646,230<br>1,533,678<br>8,435<br>301,802<br>206,482<br>629,819<br>1,146,538<br>(107,439)<br>1,039,099<br>2,572,777<br>148,342<br>1,114,976<br>1,309,459<br>2,424,435<br>2,572,777|**2023**<br>**£**<br>**£**<br>887,448<br>646,230<br>1,533,678<br>8,435<br>301,802<br>206,482<br>629,819<br>1,146,538<br>(107,439)<br>1,039,099<br>2,572,777<br>148,342<br>1,114,976<br>1,309,459<br>2,424,435<br>2,572,777|
|---|---|---|---|
||||1,533,678<br>1,039,099|
||||2,572,777|
||||148,342<br>2,424,435|
||||2,572,777|



The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2024, although an audit has been carried out under section 144 of the Charities Act 2011. 

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. 

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476. 

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. 

The financial statements were approved by the Trustees on 25 June 2025 


Mr Christopher R. G. Matthews Maxwell (Chair) 

**Trustee** 


Mrs W J Davies (Treasurer) **Trustee** 

**Company Registration No. 11911752** 

- 25 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **STATEMENT OF CASH FLOWS** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

|**Notes**<br>**Cash flows from operating activities**<br>Cash generated from/(absorbed by)<br>operations<br>**30**<br>**Investing activities**<br>Purchase of tangible fixed assets<br>Purchase of other investments<br>Proceeds on disposal of other investments<br>Other investment movements<br>Investment income received<br>**Net cash generated from/(used in)**<br>**investing activities**<br>**Net cash used in financing activities**<br>**Net increase/(decrease) in cash and cash**<br>**equivalents**<br>Cash and cash equivalents at beginning of year<br>**Cash and cash equivalents at end of year**<br>**Relating to:**<br>Cash at bank and in hand<br>Short term deposits included in current<br>asset investments|**2024**<br>**£**<br>**£**<br>638,443<br>(13,120)<br>(80,155)<br>74,539<br>(309)<br>38,431<br>19,386<br>-<br>657,829<br>836,301<br>1,494,130<br>1,180,908<br>313,222|**2023**<br>**£**<br>**£**<br>(525,632)<br>(33,360)<br>(118,518)<br>111,022<br>3,705<br>34,057<br>(3,094)<br>-<br>(528,726)<br>1,365,027<br>836,301<br>629,819<br>206,482|
|---|---|---|



- 26 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **1 Accounting policies** 

## **Charity information** 

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales (number: 11911752), a charity registered in England and Wales (number: 1183890) and Scotland (number: SC049802). The address of its registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG. 

## **1.1 Accounting convention** 

The financial statements have been prepared in accordance with the Charity's governing document, the Charities Act 2011, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)" and FRS102. The Charity is a Public Benefit Entity as defined by FRS 102. 

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £. 

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below. 

Consolidated group financial statements have not been prepared in the current year as the sole subsidiary Leukaemia Care Trading Limited has been excluded from the group accounts. Its inclusion is not material for the purpose of giving a true and fair view due to it being virtually dormant. As the sole subsidiary has been excluded the requirement to prepare consolidated accounts does not apply and hence these are charity only financial statements. 

## **1.2 Going concern** 

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future and that there are no material uncertainties about its ability to continue. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. 

## **1.3 Charitable funds** 

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives. 

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements. 

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements. 

## **1.4 Income** 

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received. 

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation. 

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected. 

- 27 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **1 Accounting policies** 

**(Continued)** 

Event income is recognised as income on receipt, as this is when it becomes measurable. 

Investment income is included in the SOFA in the year in which it is receivable. 

Voluntary income is recognised as income when receivable, except insofar as when it is incapable of financial measurement. 

## **1.5 Expenditure** 

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably. 

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use. 

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense.  Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis.  Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each. 

## **1.6 Tangible fixed assets** 

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. 

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases: 

Freehold buildings over 50 years Computers and other equipment over 3 or 4 years Fixtures and fittings over 10 years 

Freehold land is not depreciated. 

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities. 

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use. 

- 28 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **1 Accounting policies** 

## **(Continued)** 

## **1.7 Fixed asset investments** 

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred. 

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. 

## **1.8 Impairment of fixed assets** 

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). 

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. 

## **1.9 Cash and cash equivalents** 

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less. 

## **1.10 Financial instruments** 

The Charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments. 

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. 

## _**Basic financial assets**_ 

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised. 

## _**Basic financial liabilities**_ 

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised. 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method. 

## _**Derecognition of financial liabilities**_ 

Financial liabilities are derecognised when the Charity’s contractual obligations expire or are discharged or cancelled. 

- 29 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **1 Accounting policies** 

## **(Continued)** 

## **1.11 Employee benefits** 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received. 

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits. 

## **1.12 Retirement benefits** 

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due. 

## **2 Critical accounting estimates and judgements** 

In the application of the Charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods. 

Freehold buildings held by the charity have been revalued during the year, by RICS qualified independent surveyors on a "Red Book" basis. Details of the valuation can be seen in note 16. 

## **3 Income from donations and legacies** 

|**Unrestricted**<br>**Restricted**<br>**funds**<br>**funds**<br>**2024**<br>**2024**<br>**£**<br>**£**<br>Donations and gifts<br>297,130<br>197,619<br>Legacies<br>911,946<br>-<br>Grants<br>77,400<br>101,764<br>1,286,476<br>299,383|**Total**<br>**Unrestricted**<br>**Restricted**<br>**funds**<br>**funds**<br>**2024**<br>**2023**<br>**2023**<br>**£**<br>**£**<br>**£**<br>494,749<br>271,297<br>179,151<br>911,946<br>165,303<br>-<br>179,164<br>154,526<br>70,000<br>1,585,859<br>591,126<br>249,151|**Total**<br>**2023**<br>**£**<br>450,448<br>165,303<br>224,526|
|---|---|---|
|||840,277|



## **4 Income from other trading activities** 

||**Unrestricted**|**Unrestricted**|
|---|---|---|
||**funds**|**funds**|
||**2024**|**2023**|
||**£**|**£**|
|Fundraising events|1,195,916|1,237,052|



- 30 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **5 Income from investments** 

||**Unrestricted**|**Unrestricted**|
|---|---|---|
||**funds**|**funds**|
||**2024**|**2023**|
||**£**|**£**|
|Rental income|-|6,475|
|Other income|11,434|9,452|
|Interest receivable|26,997|18,130|
||38,431|34,057|



## **6 Other income** 

||**Unrestricted**|Unrestricted|
|---|---|---|
||**funds**|funds|
||**2024**|2023|
||**£**|£|
|Solar panels|1,493|963|



- 31 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **7 Raising funds** 

||**Unrestricted**|Unrestricted|
|---|---|---|
||**funds**|funds|
||**2024**|2023|
||**£**|£|
|Fundraising and publicity|||
|Staging fundraising events|244,819|313,862|
|Advertising|16,954|48,883|
|Other fundraising costs|102,162|114,339|
|Staff costs|417,651|540,476|
|Depreciation and impairment|3,334|4,866|
|Investment management fees|5,514|5,661|
|Support costs (see note 10)|65,966|59,767|
|Governance costs (see note 10)|4,652|5,135|
|Fundraising and publicity|861,052|1,092,989|



- 32 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **8 Charitable activities** 

|Staff costs<br>Depreciation and impairment<br>Patient Services costs<br>Conferences<br>Help Line costs<br>Leukaemia Matters/ Nursing Matters<br>Campaign costs<br>Other charitable activities<br>Nurse e-learning tool<br>GP's e-learning tool<br>Grants to individuals<br>Database costs<br>Patient Advocacy<br>Website costs<br>Press<br>Share of support costs (see note 9)<br>Share of governance costs (see note 9)<br>**Analysis by fund**<br>Unrestricted funds<br>Restricted funds|**2024**<br>**£**<br>799,035<br>22,766<br>102,686<br>1,679<br>4,604<br>26,100<br>36,812<br>6,527<br>309<br>-<br>119,200<br>6,611<br>1,075<br>19,565<br>5,629<br>1,152,598<br>138,012<br>9,707<br>1,300,317<br>1,076,141<br>224,176<br>1,300,317|**2023**<br>**£**<br>790,993<br>33,236<br>112,182<br>2,126<br>6,722<br>34,315<br>76,151<br>6,685<br>3,056<br>7,099<br>155,500<br>7,037<br>1,481<br>32,718<br>9,159|
|---|---|---|
|||1,278,460<br>124,689<br>11,981|
|||1,415,130|
|||1,158,403<br>256,727|
|||1,415,130|



- 33 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **9 Support costs** 

|Staff costs<br>Other staff costs<br>Rent, rates and<br>insurance<br>Heat and light<br>Repairs and renewals<br>Printing, postage and<br>stationery<br>Telephone<br>Motor and other travel<br>Subscribtions<br>Other office costs<br>Bank charges<br>Sundry Expenses<br>Audit fees<br>Legal and professional<br>Trustee and meeting<br>expenses<br>Analysed between<br>Fundraising<br>Charitable activities|**Support**<br>**costs**<br>**Governance**<br>**costs**<br>**£**<br>**£**<br>34,528<br>-<br>23,585<br>-<br>14,566<br>-<br>12,402<br>-<br>19,256<br>-<br>13,031<br>-<br>13,346<br>-<br>756<br>-<br>2,924<br>-<br>49,914<br>-<br>1,157<br>-<br>18,513<br>-<br>-<br>5,400<br>-<br>5,128<br>-<br>3,831<br>203,978<br>14,359<br>65,966<br>4,652<br>138,012<br>9,707<br>203,978<br>14,359|**2024**Support costs Governance<br>costs<br>**£**<br>£<br>£<br>34,528<br>22,157<br>-<br>23,585<br>43,500<br>-<br>14,566<br>12,515<br>-<br>12,402<br>12,000<br>-<br>19,256<br>13,415<br>-<br>13,031<br>17,237<br>-<br>13,346<br>11,486<br>-<br>756<br>858<br>-<br>2,924<br>2,488<br>-<br>49,914<br>30,303<br>-<br>1,157<br>1,201<br>-<br>18,513<br>17,296<br>-<br>5,400<br>-<br>6,600<br>5,128<br>-<br>3,419<br>3,831<br>-<br>7,097<br>218,337<br>184,456<br>17,116<br>70,618<br>59,767<br>5,135<br>147,719<br>124,689<br>11,981<br>218,337<br>184,456<br>17,116|2023<br>£<br>22,157<br>43,500<br>12,515<br>12,000<br>13,415<br>17,237<br>11,486<br>858<br>2,488<br>30,303<br>1,201<br>17,296<br>6,600<br>3,419<br>7,097|
|---|---|---|---|
||||201,572|
||||64,902<br>136,670|
||||201,572|



## **10 Auditor's remuneration** 

|The analysis of auditor's remuneration is as follows:|||
|---|---|---|
|**Fees payable**|**2024**|**2023**|
||**£**|**£**|
|Audit of the annual accounts|5,400|6,600|



## **11 Trustees** 

The Charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business.  The costs reimbursed to 2 (2023 : 2) trustees for the current year were  £3,831 (2023 : £5,748). 

None of the Trustees (or any persons connected with them) received any remuneration during the year. 

- 34 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **11 Trustees** 

## **(Continued)** 

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arms length basis and the amount paid during the year amounted to £3,045 (2023 : £3,069). 

All trustees are covered by an indemnity insurance policy costing £906 (2023: £844) 

## **12 Employees** 

The average monthly number of employees during the year was: 

|Training and provision of care<br>Fundraising and publicity<br>Accounts and administration<br>Total<br>**Employment costs**<br>Wages and salaries<br>Social security costs<br>Other pension costs|**2024**<br>**Number**<br>24<br>17<br>5<br>46<br>**2024**<br>**£**<br>1,109,848<br>95,587<br>45,779<br>1,251,214|**2023**<br>**Number**<br>27<br>22<br>5|
|---|---|---|
|||54|
|||**2023**<br>**£**<br>1,205,124<br>101,407<br>47,095|
|||1,353,626|



Redundancy and termination payments totalling £25,484 were made in the reporting period. 

The remuneration of key management personnel through payroll and other fees is £191,758 (2023: £204,181). 

The number of employees whose annual remuneration was more than £60,000 is as follows: 

|The number of employees whose annual remuneration was more than £60,000<br>is as follows:|||
|---|---|---|
|£60,001 to £70,000<br>**13**<br>**Other material expenditure**|**2024**<br>**Number**<br>2|**2023**<br>**Number**<br>1|
||||



Other material expenditure in the prior year related to a provision for the intercompany debtor. 

- 35 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **14 Net gains on investments** 

|Revaluation of investments<br>Gains on sale of investments|**2024**<br>**£**<br>46,609<br>-<br>46,609|2023<br>£<br>24,702<br>5,930|
|---|---|---|
|||30,632|



## **15 Taxation** 

There is no taxation payable during the year as the activities undertaken by Leukaemia Care fall within the charitable objectives of the charity. 

## **16 Tangible fixed assets** 

|**Cost or valuation**<br>At 1 January 2024<br>Additions<br>Disposals<br>Revaluation<br>At 31 December 2024<br>**Depreciation and impairment**<br>At 1 January 2024<br>Depreciation charged in the year<br>Eliminated in respect of disposals<br>At 31 December 2024<br>**Carrying amount**<br>At 31 December 2024<br>At 31 December 2023|**Freehold**<br>**buildings**<br>**Computers**<br>**and other**<br>**equipment**<br>**Fixtures and**<br>**fittings**<br>**£**<br>**£**<br>**£**<br>842,598<br>126,165<br>14,656<br>-<br>13,120<br>-<br>-<br>(31,093)<br>-<br>(67,598)<br>-<br>-<br>775,000<br>108,192<br>14,656<br>-<br>82,121<br>13,851<br>-<br>25,611<br>489<br>-<br>(31,093)<br>-<br>-<br>76,639<br>14,340<br>775,000<br>31,553<br>316<br>842,599<br>44,044<br>805|**Total**<br>**£**<br>983,419<br>13,120<br>(31,093)<br>(67,598)|
|---|---|---|
|||897,848|
|||95,972<br>26,100<br>(31,093)|
|||90,979|
|||806,869|
|||887,448|



Land and buildings with a carrying amount of ££775,000 were revalued at 2 July 2024 by Clarke & Jay Chartered Surveyors, independent valuers not connected with the Charity. The valuation conforms to RICS Valuation - Global Standards 2022 - "Red Book" and was based on current market valuation. 

At 31 December 2024, had the revalued assets been carried at historic cost less accumulated depreciation and accumulated impairment losses, their carrying amount would have been approximately £842,599 (2023: £842,599). 

- 36 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **17 Fixed asset investments** 

|**Listed**<br>**investments**<br>**Cash in**<br>**portfolio**<br>**Other**<br>**investments**<br>**£**<br>**Cost or valuation**<br>At 1 January 2024<br>637,165<br>8,965<br>100<br>Additions<br>80,155<br>(80,155)<br>-<br>Valuation changes<br>46,609<br>-<br>-<br>Other cash movements<br>-<br>5,925<br>-<br>Disposals<br>(74,539)<br>74,539<br>-<br>At 31 December 2024<br>689,390<br>9,274<br>100<br>**Carrying amount**<br>At 31 December 2024<br>689,390<br>9,274<br>100<br>At 31 December 2023<br>637,165<br>8,965<br>100<br>**2024**<br>Other investments comprise:<br>**Notes**<br>**£**<br>Investments in subsidiaries<br>**28**<br>100<br>**18**<br>**Financial instruments**<br>**2024**<br>**£**<br>**Carrying amount of financial assets**<br>Instruments measured at fair value through profit or loss<br>689,390<br>**19**<br>**Stocks**<br>**2024**<br>**£**<br>Finished goods and goods for resale<br>-|**Total**<br>**£**<br>646,230<br>-<br>46,609<br>5,925<br>-|
|---|---|
||698,764|
||698,764|
||646,230|
||**2023**<br>**£**<br>100|
||**2023**<br>**£**<br>637,165|
||**2023**<br>**£**<br>8,435|



- 37 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

|**20**<br>**Debtors**<br>**Amounts falling due within one year:**<br>Trade debtors<br>Amounts owed by subsidiary undertakings<br>Other debtors<br>Prepayments and accrued income<br>**21**<br>**Current asset investments**<br>Term deposits<br>**22**<br>**Creditors: amounts falling due within one year**<br>Other taxation and social security<br>Trade creditors<br>Accruals<br>**23**<br>**Retirement benefit schemes**<br>**Defined contribution schemes**<br>Charge to profit or loss in respect of defined contribution schemes|**2024**<br>**£**<br>51,994<br>2,084<br>300<br>277,944<br>332,322<br>**2024**<br>**£**<br>313,222<br>**2024**<br>**£**<br>26,833<br>23,486<br>69,648<br>119,967<br>**2024**<br>**£**<br>45,779|**2023**<br>**£**<br>51,266<br>-<br>147<br>250,389|
|---|---|---|
|||301,802|
|||**2023**<br>**£**<br>206,482|
|||**2023**<br>**£**<br>28,981<br>22,137<br>56,321|
|||107,439|
|||**2023**<br>**£**<br>47,095|



The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund. 

- 38 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## 

|**Restricted funds**|The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may|be used.|**Movement in funds**<br>**Movement in funds**|**Balance at 1**<br>**Income**<br>**Expenditure**<br>**Balance at**<br>**Income**<br>**Expenditure**<br>**Balance at**|**January 2023**<br>**1 January 2024**<br>**31 December**|**2024**|**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**|The Lily Blaen Hope Fund<br>9,384<br>-<br>(9,384)<br>-<br>-<br>-<br>-|Information Booklets<br>-<br>5,985<br>-<br>5,985<br>27,575<br>(33,120)<br>440|GP e-learning Tool<br>-<br>25,000<br>(25,000)<br>-<br>-<br>-<br>-|Nurse Advisor<br>-<br>-<br>-<br>-<br>45,764<br>(8,452)<br>37,312|Student/ Education<br>5,000<br>-<br>(5,000)<br>-<br>-<br>-<br>-|Glasgow Area<br>300<br>10,000<br>(7,471)<br>2,829<br>5,600<br>(6,396)<br>2,033|Support Group - Scotland<br>3,334<br>-<br>(756)<br>2,578<br>-<br>1,080<br>1,498|Counselling Fund<br>870<br>15,000<br>(15,870)<br>-<br>-<br>-<br>-|Support Group - Glasgow & Aberdeen<br>958<br>-<br>(958)<br>-<br>-<br>-<br>-|Support Group - Leicetershire<br>1,393<br>2,000<br>(278)<br>3,115<br>500<br>-<br>3,615|Birmingham Patient Conference<br>500<br>-<br>(500)<br>-<br>-<br>-<br>-|Belfast Hospital Support<br>11,999<br>-<br>-<br>11,999<br>3,000<br>(8,325)<br>6,674|Bristol Hospital Support<br>1,131<br>5,000<br>(5,725)<br>406<br>6,062<br>(6,468)<br>-|Financial Grants<br>-<br>60,000<br>(60,000)<br>-<br>30,000<br>(30,000)<br>-|Care Helpline Costs<br>-<br>5,000<br>(5,000)<br>-<br>-<br>-<br>-|Buddy Scheme<br>-<br>200<br>(200)<br>-<br>20,000<br>(12,330)<br>7,670|West Midlands Hospital Support<br>-<br>5,593<br>(5,593)<br>-<br>29,000<br>(12,497)<br>16,503|Spot Leukaemia<br>-<br>30,000<br>(30,000)<br>-<br>15,000<br>(15,000)<br>-|Newcastle Hospital Support<br>1,000<br>6,600<br>(3,294)<br>4,306<br>7,800<br>(7,994)<br>4,112|UCHL Hospital Support<br>1,015<br>-<br>(1,015)<br>-<br>-<br>-<br>-|Manchester Hospital Support<br>4,026<br>3,000<br>(4,196)<br>2,830<br>6,125<br>(6,418)<br>2,537|Nottingham Hospital Support<br>9,454<br>2,000<br>-<br>11,454<br>2,500<br>(4,210)<br>9,744|Patient Support Scotland<br>-<br>5,000<br>(3,294)<br>1,706<br>-<br>(750)<br>956|- 39 -|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**24**||||||||||||||||||||||||||||||||





Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## 

## 

|**(Continued)**|33,228|-|-|-|3,383|28,125|-|3,000|608|-|7,000|10,689|11,017|1,458|1|6,000|3,776|3,000|156|4,665|6,102|1,000|6,447|-|800|-|223,549|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
||(300)|-|-|-|(353)|(7,166)|-|-|(432)|-|-|-|(5,895)|(7,591)|(7,789)|-|(4,224)|-|(756)|(9,981)|(5,398)|-|(9,553)|(7,184)|(450)|(4,064)|(224,176)|
||-|-|-|-|-|31,680|-|1,000|-|-|-|8,189|9,300|-|5,790|-|-|-|-|7,500|8,500|-|16,000|7,184|1,250|4,064|299,383|
||33,528|-|-|-|3,736|3,611|-|2,000|1,040|-|7,000|2,500|7,612|9,049|2,000|6,000|8,000|3,000|912|7,146|3,000|1,000|-|-|-|-|148,342|
||(10,990)|(10,000)|(15,000)|(23,135)|(4,610)|(354)|(590)|-|(540)|(5,000)|-|-|-|(392)|-|-|-|-|(1,728)|(854)|-|-|-|-|-|-|(256,727)|
||-|-|-|-|-|-|-|2,000|1,580|5,000|7,000|2,500|7,612|9,441|2,000|6,000|8,000|3,000|2,640|8,000|3,000|1,000|-|-|-|-|249,151|
||44,518|10,000|15,000|23,135|8,346|3,965|590|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|155,918|
|**Restricted funds**|William Davidson - Aberdeen Area|CAR-T|AML Information|AML Education|Yorkshire Patient Support|Wales Hospital Support|Support Group Wales|Oxfordshire Hospital Support|Support Group Leeds|Good Hope Hospital Support|Glasgow Hospital Support|Northern Ireland Hospital Support|NNUH Hospital Support|Plymouth/Devon|Cambridge|Merseyside|Swindon Hospital Supports|Guy's & St Thomas Hospital Support|Support Group Manchester|Dorset (Bournemouth)|Brighton|Aberdeen|Southhampton Hospital Support|Leeds Hospital Support|Patient Support Reading|Hospital Hubs||
|**24**||||||||||||||||||||||||||||





Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## 

## 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## 

## 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## 

## 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **25 Designated funds** 

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes. 

|**Balance at 1**<br>**January 2023**<br>**£**<br>Fixed asset fund<br>879,551<br>Strategic implementation fund<br>468,272<br>1,347,823|**Transfers**<br>**Balance at**<br>**1 January 2024**<br>**£**<br>**£**<br>7,897<br>887,448<br>(240,744)<br>227,528<br>(232,847)<br>1,114,976|**Transfers**<br>**Balance at**<br>**31 December**<br>**2024**<br>**£**<br>**£**<br>(80,579)<br>806,869<br>239,905<br>467,433<br>159,326<br>1,274,302|**Transfers**<br>**Balance at**<br>**31 December**<br>**2024**<br>**£**<br>**£**<br>(80,579)<br>806,869<br>239,905<br>467,433<br>159,326<br>1,274,302|
|---|---|---|---|
||||1,274,302|



Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity. 

Strategic Implementation Fund: funds to support the delivery of strategy adopted by the Board of Trustees. 

## **26 Analysis of net assets between funds** 

|**Analysis of net assets between funds**||||
|---|---|---|---|
|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**2024**<br>**2024**<br>**£**<br>**£**<br>Fund balances are<br>represented by:<br>Tangible assets<br>806,869<br>-<br>Investments<br>698,764<br>-<br>Current assets/(liabilities)<br>1,482,936<br>223,549<br>2,988,569<br>223,549|**Total**<br>Unrestricted<br>funds<br>**2024**<br>2023<br>**£**<br>£<br>806,869<br>887,448<br>698,764<br>646,230<br>1,706,485<br>890,757<br>3,212,118<br>2,424,435|Restricted<br>funds<br>2023<br>£<br>-<br>-<br>148,342<br>148,342|Total<br>2023<br>£<br>887,448<br>646,230<br>1,039,099|
||||2,572,777|



## **27 Related party transactions** 

There were no disclosable related party transactions during the year (2023 - none) other than as disclosed in note 11. 

- 44 - 



Docusign Envelope ID: 280EA696-2D4F-4825-8550-11E325E3A559 

## **LEUKAEMIA CARE** 

## **NOTES TO THE  FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 DECEMBER 2024**_ 

## **28 Subsidiaries** 

These financial statements are separate Charity financial statements for Leukaemia Care. 

Details of the Charity's subsidiaries at 31 December 2024 are as follows: 

||**Name of undertaking**<br>**Registered**|**Nature of business**|**Nature of business**|**Class of**|**% Held**|**% Held**||
|---|---|---|---|---|---|---|---|
||**office**|||**shares held**<br>**Direct **||**Indirect**||
||Leukaemia Care Trading<br>England|Unicorn walk||Ordinary|100.00|||
||Limited|||||||
||The aggregate capital and reserves and the result||for the year was as follows:|||||
||**Name of undertaking**<br>**Profit/(Loss)**||**Capital and**|||||
||||**Reserves**|||||
|||**£**|**£**|||||
||Leukaemia Care Trading|||||||
||Limited<br>(3,964)||(205,679)|||||
|**29**|**Analysis of changes in net funds**|||||||
||The Charity had no material debt during the year.|||||||
|**30**|**Cash generated from operations**||||**2024**|**2023**||
||||||**£**|**£**||
||Surplus/(deficit) for the year|||706,939||(567,268)||
||Adjustments for:|||||||
||Investment income recognised in statement of financial activities|||(38,431)||(34,057)||
||Gain on disposal of investments||||-|(5,930)||
||Fair value gains and losses on investments|||(46,609)||(24,702)||
||Depreciation and impairment of tangible fixed assets||||26,101|38,103||
||Movements in working capital:|||||||
||Decrease/(increase) in stocks||||8,435|(2,210)||
||(Increase)/decrease in debtors|||(30,520)||95,048||
||Increase/(decrease) in creditors||||12,528|(24,616)||
||**Cash generated from/(absorbed by) operations**|||638,443||(525,632)||



- 45 -